The findings of these studies demonstrate that SGLT2 inhibitors reduce cardiorenal risk even in participants in low KDIGO risk categories, suggesting that SGLT2 inhibitors may have benefits in the prevention of diabetic kidney disease in people who do not have CKD at baseline. The gene discussed is SLC5A2; the disease is chronic kidney disease.